Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Centessa Pharmaceuticals plc ADR shares valued at $64,028 were purchased by SAHA SAURABH on Nov 21 ’24. At $18.24 per share, SAHA SAURABH acquired 3,511 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, SAHA SAURABH purchased 55,000 shares, netting a total of over 933,350 in proceeds.
Before that, SAHA SAURABH had sold 32,023 shares from its account. In a trade valued at $585,419, the Chief Executive Officer traded Centessa Pharmaceuticals plc ADR shares for $18.28 each. Upon closing the transaction, the insider’s holdings decreased to 32,023 shares, worth approximately $11.47 million.
As published in a research note from Morgan Stanley on September 20, 2024, Centessa Pharmaceuticals plc ADR [CNTA] has been rated up from an Equal-weight to an Overweight and the price target has been revised to $26 from $11. Analysts at B. Riley Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. As of July 18, 2024, Oppenheimer has initiated its “an Outperform” rating for CNTA. Earlier on November 15, 2023, Jefferies upgraded its rating. Their new recommendation was “a Buy” for CNTA stock which previously was a “a Hold”.
Analyzing CNTA Stock Performance
During the last five days, there has been a surge of approximately 3.94%. Over the course of the year, Centessa Pharmaceuticals plc ADR shares have jumped approximately 128.52%. Shares of the company reached a 52-week high of $18.74 on 11/13/24 and a 52-week low of $6.65 on 01/11/24. A 50-day SMA is recorded $16.09, while a 200-day SMA reached $11.85. Nevertheless, trading volume fell to 0.63 million shares from 0.71 million shares the previous day.
Support And Resistance Levels for Centessa Pharmaceuticals plc ADR (CNTA)
According to the 24-hour chart, there is a support level at 16.32, which, if violated, would cause prices to drop to 14.44. In the upper region, resistance lies at 19.18. The next price resistance is at 20.16. RSI (Relative Strength Index) is 64.60 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.56, which suggests the price will decrease in the coming days. Percent R is at 14.71%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
